Literature DB >> 15528045

Identification and quantification of N(epsilon)-(Hexanoyl)lysine in human urine by liquid chromatography/tandem mass spectrometry.

Yoji Kato1, Akihiro Yoshida, Michitaka Naito, Yoshichika Kawai, Kentaro Tsuji, Masayasu Kitamura, Noritoshi Kitamoto, Toshihiko Osawa.   

Abstract

The identification and quantification of N(epsilon)-(hexanoyl)lysine (N(epsilon)-HEL), which was found from the reactions between lipid hydroperoxide and lysine, from human urine was examined using liquid chromatography/tandem mass spectrometry (LC/MS/MS). The N(epsilon)-HEL in the partially purified urine fraction was identified using LC/MS/MS by several approaches including precursor/product ion scans. The peak found by the multiple-reaction monitoring (MRM) of the collision-induced fragmentation of N(epsilon)-HEL was clearly observed in urine, and the elution position coincided with the synthetic standard N(epsilon)-HEL. The product, estimated N(epsilon)-HEL, was absorbed by a specific antibody to N(epsilon)-HEL. Moreover, N(alpha)-HEL, one of the plausible hexanoyl adducts from the reaction between the N(alpha) moiety of L-lysine and the peroxidized lipid, was hardly detected in urine samples, suggesting that the origin of the N(epsilon)-HEL is the peroxidized lipid-modified proteins but not artificial hexanoylated L-lysine. Using the MRM technique, the amount of urinary N(epsilon)-HEL from the control subjects (observed healthy) was estimated to be 1.58 +/- 0.23 mumol/mol of creatinine. A comparative study of the urinary N(epsilon)-HEL with an oxidative stress marker, 8-oxo-7,8-dihydro-2'-deoxyguanosine, showed a high correlation (r = 0.844) between the two biomarkers. Furthermore, the quantification of N(epsilon)-HEL in the control and diabetic urines revealed that the urinary N(epsilon)-HEL from diabetic subjects (3.21 +/- 0.65 mumol/mol of creatinine) was significantly higher than that from the control subjects.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15528045     DOI: 10.1016/j.freeradbiomed.2004.09.007

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  6 in total

1.  Lactobacillus johnsonii N6.2 mitigates the development of type 1 diabetes in BB-DP rats.

Authors:  Ricardo Valladares; Dhyana Sankar; Nan Li; Emily Williams; Kin-Kwan Lai; Asmaa Sayed Abdelgeliel; Claudio F Gonzalez; Clive H Wasserfall; Joseph Larkin; Desmond Schatz; Mark A Atkinson; Eric W Triplett; Josef Neu; Graciela L Lorca
Journal:  PLoS One       Date:  2010-05-06       Impact factor: 3.240

2.  Lipid-lysine adducts and modified tyrosines as markers of oxidative stress in the second trimester of pregnancy and their association with infant characteristics.

Authors:  Barbara Rejc; Yoji Kato; Natasa Karas-Kuzelicki; Josko Osredkar; Ksenija Gersak
Journal:  Exp Ther Med       Date:  2016-01-12       Impact factor: 2.447

3.  Etanercept reduces the oxidative stress marker levels in patients with rheumatoid arthritis.

Authors:  Yasunori Kageyama; Masaaki Takahashi; Tetsuyuki Nagafusa; Eiji Torikai; Akira Nagano
Journal:  Rheumatol Int       Date:  2007-07-28       Impact factor: 2.631

4.  Alterations in plasma triglycerides and ceramides: links with cardiac function in humans with type 2 diabetes.

Authors:  Linda R Peterson; Xuntian Jiang; Ling Chen; Anne C Goldberg; Marsha S Farmer; Daniel S Ory; Jean E Schaffer
Journal:  J Lipid Res       Date:  2020-05-11       Impact factor: 5.922

5.  New covalent modifications of phosphatidylethanolamine by alkanals: mass spectrometry based structural characterization and biological effects.

Authors:  Andrea Annibal; Kristin Schubert; Ulf Wagner; Ralf Hoffmann; Jürgen Schiller; Maria Fedorova
Journal:  J Mass Spectrom       Date:  2014-07       Impact factor: 1.982

6.  Quantification of Modified Tyrosines in Healthy and Diabetic Human Urine using Liquid Chromatography/Tandem Mass Spectrometry.

Authors:  Yoji Kato; Natsuko Dozaki; Toshiyuki Nakamura; Noritoshi Kitamoto; Akihiro Yoshida; Michitaka Naito; Masayasu Kitamura; Toshihiko Osawa
Journal:  J Clin Biochem Nutr       Date:  2008-12-27       Impact factor: 3.114

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.